ABT-751 (E7010)

For research use only. Not for use in humans.

目录号:S1165

ABT-751 (E7010) Chemical Structure

CAS No. 141430-65-1

ABT-751 (E7010)与β-tubulin的秋水仙素位点结合,抑制微管的聚合,不抑制MDR转运的底物,且作用于抗Vincristine, Doxorubicin,和Cisplatin的细胞系有效。Phase 1/2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1316.31 现货
RMB 973.47 现货
RMB 12858.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的ABT-751 (E7010)发表文献5篇:

客户使用该产品的3个实验数据:

  • Cell viability in H292 monolayer cells after 3-day treatment and spheroid volume in H292 3D cultureafter 7-day treatment with ABT751. Data points are means ?SD for three individual experiments. IC50 values were calculated to emphasize the differences in drug potency in 2D verses 3D cultures. ABT751, IC50 of 177.2 ?17.3 nM for 2D and 670.2 ?257.6 nM for 3D.

    Bioorg Med Chem 2013 21, 922-31. ABT-751 (E7010) purchased from Selleck.

    3D spheroid integrity following treatment with ABT751. Representative phase contrast imaginesof H292 multi-cellular 3D spheroid at the onset of the treatment and after a 7-day treatment interval with various concentrations. Magnification: 10 X objective, scan bar:200 μm. Dose and time dependent curves of ABT751 with 3D spheroid assay.

    Bioorg Med Chem 2013 21, 922-31. ABT-751 (E7010) purchased from Selleck.

  • Western blot analysiswas used to validate the regulation of β1-tubulin to vinculin. (A) Inhibited effects of ABT-751 on the β1-tubulin.Washed human plateletswere treatedwith 0, 2.5, 5, 10 and 20 μg/ml ABT-751 for 60 min then stimulated with 0.3 U thrombin (B) Protein expression of vinculin and Talin1 in washed platelets. The representative bands were from different gels for repeated experiments. After densitometric analysis, the values of proteins were normalized against GAPDH, respectively. Data are shown as the mean ± S.D. (n =3-4 per group). ##P < 0.01 vs normal group, **P < 0.01 vs thrombin group, ++P < 0.01 vs thrombin group.

    Fitoterapia, 2017, 116:106-115. ABT-751 (E7010) purchased from Selleck.

产品安全说明书

Microtubule Associated抑制剂选择性比较

生物活性

产品描述 ABT-751 (E7010)与β-tubulin的秋水仙素位点结合,抑制微管的聚合,不抑制MDR转运的底物,且作用于抗Vincristine, Doxorubicin,和Cisplatin的细胞系有效。Phase 1/2。
特性 ABT-751 是口服生物有效性的,与微管蛋白结合,抗有丝分裂的硫安类药剂。
靶点
Microtubules [1]
体外研究

体外,ABT-751作用于神经母细胞瘤时,IC50为0.6–2.6 μM,作用于其他实体瘤细胞系时,IC50为0.7–4.6 μM,且具有选择毒性。而且, ABT-751也选择性作用于动态微管, 可用于解释浓度为ABT-751的IC90时的浓度时,α-微管阳性聚合小管持续乙酰化。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT-15 cell MXHQdo9tcW[ncnH0bY9vKGG|c3H5 MlPERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiClb3zvckBk[XKlaX7vcYEhUEOWLUG1JINmdGxibHnu[UhOTFJqLTmpMEBKSzVyPUCuN|Qh|ryP MnnJNVE1OjV3M{S=
HCT116-C9 cell NHLP[ldHfW6ldHnvckBie3OjeR?= NHHDVHBG\m[nY4TpeoUh[2:wY3XueJJifGmxbjD0c{BqdmirYnn0JINmdGxicILvcIln\XKjdHnvckBjgSB3MDWgdoVt[XSrdnWgeI8hfW62cnXheIVlKGOxboTyc4wh[2WubDDh[pRmeiB5MjDodkBw\iClb370bY52d3W|IHX4dI9{fXKnIHnuJGhEXDFzNj3DPUBk\WyuIHzpcoUtKEmFNUC9NE46KM7:TR?= MXyxNlM5OzBzNx?=
NCI-H460 cell M{TJ[nBzd2yrZnXyZZRqd25iYYPzZZk> NYLnbFk1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDseY5oKGOjcnPpco9u[SCQQ1mtTFQ3OCClZXzsJIxqdmViKF3EVkgsMSluIFnDOVA:OC5|NTFOwG0> NYru[YppOTF2MkW1N|Q>
P388 cell line NWTqU5VMTnWwY4Tpc44h[XO|YYm= NILU[IQ4OiCq Mmn0SYZn\WO2aY\lJINwdmOnboTyZZRqd25idH:gbY5pcWKrdDDj[YxtKHC{b3zp[oVz[XSrb36gZpkhPTBnIILlcIF1cX[nIITvJJVvfHKnYYTl[EBkd262cn;sJINmdGxiYX\0[ZIhPzJiaIKgc4Yh[2:wdHnueY92eyCneIDvd5Vz\SCrbjDQN|g5KGOnbHygcIlv\e,:jDDJR|UxRTBwMUmg{txO NFTaXnkyOjN6M{CxOy=>
P388/4.0 r-M cell line M1:zXmZ2dmO2aX;uJIF{e2G7 NXTWVpBzPzJiaB?= NYrpcIcyTW[oZXP0bZZmKGOxbnPlcpRz[XSrb36geI8hcW6qaXLpeEBk\WyuIIDyc4xq\mW{YYTpc44h[nliNUClJJJmdGG2aY\lJJRwKHWwdILlZZRm\CClb370do9tKGOnbHygZYZ1\XJiN{KgbJIhd2ZiY3;ueIlvfW:3czDlfJBwe3W{ZTDpckBROzh6L{SuNEBzNU1iY3XscEBtcW6nLDDJR|UxRTF3IN88US=> NGfMclUyOjN6M{CxOy=>
human HL60 cells NEPCSFlRem:uaX\ldoF1cW:wIHHzd4F6 Mof2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|LDDJR|UxRTBwM{Sg{txO NFzndWIyPzJ5NkC1Oi=>
HeLa cells NG\WZnJEgXSxdH;4bYNqfHliYYPzZZk> M4LiZlQ5NTd{IHi= M{XucmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghfG9iN{KgbJJ{KGK7IGfBWE0yKGG|c3H5MEBKSzVyPUCuNlch|ryP MVqyNVEzPjB{Nx?=
MDR1 cells NHHBcohEgXSxdH;4bYNqfHliYYPzZZk> NUi0[IIxPDhvN{KgbC=> MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuSUSULWLFV{BmgHC{ZYPzbY5oKE2GUkGgZ4VtdHNiYX\0[ZIhPDhidH:gO|IhcHK|IHL5JHdCXC1zIHHzd4F6NCCLQ{WwQVAvOjlizszN MXGyNVEzPjB{Nx?=
Jurkat cells NI\Yc|dHfW6ldHnvckBie3OjeR?= NFXXOmszPCCq M1zDTmNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGp2emujdDDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG|ZTDh[pRmeiB{NDDodpMhfXOrbnegdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDifUBHSUOVIHHuZYx6e2m|LDDJR|UxRTBwMU[g{txO NHTCT|QzOTF{NkCyOy=>
SW620 cells M3P3U2N6fG:2b4jpZ4l1gSCjc4PhfS=> MYS0PE04OiCq MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTW|YzOCClZXzsd{Bi\nSncjC0PEB1dyB5MjDodpMh[nliV1HUMVEh[XO|YYmsJGlEPTB;MD6xPUDPxE1? NIq0R40zOTF{NkCyOy=>
A2780 cells NV7aTZhlS3m2b4TvfIlkcXS7IHHzd4F6 NIj2fnM1QC15MjDo M{DxW2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGEzPzhyIHPlcIx{KGGodHXyJFQ5KHSxIEeyJIhzeyCkeTDXRXQuOSCjc4PhfUwhUUN3ME2wMlE4KM7:TR?= NG\P[nczOTF{NkCyOy=>
HT-29 cells MXTQdo9tcW[ncnH0bY9vKGG|c3H5 MUe3NkBp MkXRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVD2yPUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMkGg{txO M1\lNlI{OjB{OES5
HUVEC MnTBSpVv[3Srb36gZZN{[Xl? MkDJNVAxNTFyMECgcm0> NIruR5o1KGh? NG\FbJlKdmS3Y4Tpc44hd2ZidnHzZ5Vt[XJiZHnzdpVxfGmwZzDhZ5Rqfmm2eTDpckBJXV[HQzDhd5Nme3OnZDDhd{BXTUeILXnu[JVk\WRidIXi[UBnd3KvYYTpc44h[XRiMUCwJJRwKDFyMECgcm0h[W[2ZYKgOEBpenNiYomgcYlkem:|Y3;wbYMh[W6jbInzbZM> MmDQNlQyODZ7OEK=
H460 cells MlPxR5l1d3SxeHnjbZR6KGG|c3H5 MY[3NkBp MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIOFYxKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBu\XSqeXzlcoUh[my3ZTDzeIFqdmmwZz3iZZNm\CCjc4PhfUwhUUN3ME2wMlIyPzdizszN MXSyOFExPjl6Mh?=
MKN45 cells NEOwdlZEgXSxdH;4bYNqfHliYYPzZZk> M3PwRlczKGh? NXnteIJFS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUuQNEWgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IH3leIh6dGWwZTDicJVmKHO2YXnubY5oNWKjc3XkJIF{e2G7LDDJR|UxRTBwMU[2JO69VQ>? NG[wWoQzPDFyNkm4Ni=>
HT-29 cells MlTJR5l1d3SxeHnjbZR6KGG|c3H5 M2jWe|czKGh? NF\uR5NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nlibXX0bJlt\W6nIHLseYUhe3SjaX7pcocu[mG|ZXSgZZN{[XluIFnDOVA:OC5|M{i3JO69VQ>? MVGyOFExPjl6Mh?=
human A549 cells M3rzNWN6fG:2b4jpZ4l1gSCjc4PhfS=> MYm0PEBp MoTzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGuN|Eh|ryP MWeyOFg{PTd6Nh?=
ACHN cells MkL0R5l1d3SxeHnjbZR6KGG|c3H5 MlfxOFghcA>? MkfvR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRWNJViClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUKuNVMh|ryP M4LKd|I1QDN3N{i2
MCF7 cells MlzBR5l1d3SxeHnjbZR6KGG|c3H5 NX;DSYlSPDhiaB?= M1Gxe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xMlI2KM7:TR?= MWKyOFg{PTd6Nh?=
HT-29 cells MXrDfZRwfG:6aXPpeJkh[XO|YYm= M{XrTlQ5KGh? Mlq0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xMlYzKM7:TR?= NH;DRW4zPDh|NUe4Oi=>
A549 cells MY\Qdo9tcW[ncnH0bY9vKGG|c3H5 NFvTNZYzPCCq NGLsUnhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgNlQhcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2xMlMyKM7:TR?= MkL6NlU1PjhyM{m=
human MCF7 cells M1HvXnBzd2yrZnXyZZRqd25iYYPzZZk> M2WyOVI1KGh? MoTqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPQ1[3JINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEK0JIhzeyCkeTDTVmIh[XO|YYmsJGdKPTB;MT6yOUDPxE1? MlTSNlU1PjhyM{m=
KB-S15 cells NFzyR|BEgXSxdH;4bYNqfHliYYPzZZk> NW\0dIM6PzJiaB?= MleyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2IuWzF3IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJHAu\3BzN{CvUWRTKGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCvZYTofYxmdmViYnz1[UB{fGGrbnnu[{1j[XOnZDDhd5NigSxiSVO1NF0xNjJyNjFOwG0> MYGyOFExPjl6Mh?=
KB-7d cells M{WzSmN6fG:2b4jpZ4l1gSCjc4PhfS=> NWLEXlc{PzJiaB?= NIXYWY9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSi15ZDDj[YxteyCxdnXy[ZhxemW|c3nu[{BOWlBiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IH3leIh6dGWwZTDicJVmKHO2YXnubY5oNWKjc3XkJIF{e2G7LDDJR|UxRTBwMkC1JO69VQ>? NIDIZo8zPDFyNkm4Ni=>
KB-VIN10 cells NVTPN4ZNS3m2b4TvfIlkcXS7IHHzd4F6 NH;scYQ4OiCq NW\GS28{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0JvVlnONVAh[2WubIOgc5ZmemW6cILld5NqdmdiUD3ndFE4OC:PRGKgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|IhcHK|IHL5JI1mfGi7bHXu[UBjdHWnIIP0ZYlvcW6pLXLhd4VlKGG|c3H5MEBKSzVyPUCuNlI4KM7:TR?= M2rnSlI1OTB4OUiy
human PC3 cells NVjCb|hOS3m2b4TvfIlkcXS7IHHzd4F6 MUm0PEBp NVf3WHBwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDR6IHjyd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKGG|c3H5MEBIUTVyPUCuOlIh|ryP M17odVI3OjRzMEOy
human AsPC1 cells MoXzR5l1d3SxeHnjbZR6KGG|c3H5 NGGwfGY1QCCq MnjnR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRZNRSzFiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO|YYmsJGdKPTB;ND6xNUDPxE1? NF7Ne|kzPjJ2MUCzNi=>
human A549 cells MXPDfZRwfG:6aXPpeJkh[XO|YYm= NGTTW4o1QCCq Mk[yR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA1QCCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygS2k2OD13LkOzJO69VQ>? MUCyOlI1OTB|Mh?=
Hep3B cells MoW2R5l1d3SxeHnjbZR6KGG|c3H5 M37VSVQ5KGh? NGrLVlBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XB|QjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhT0l3ME2wMlg1KM7:TR?= NVfr[Fd5OjZ{NEGwN|I>
KB cells MXjDfZRwfG:6aXPpeJkh[XO|YYm= MlvSO|IhcA>? M{TVT2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBu\XSqeXzlcoUh[my3ZTDzeIFqdmmwZz3iZZNm\CCjc4PhfUwhUUN3ME2wMlI2OTNizszN MWOyOFExPjl6Mh?=
DU145 cells NWLr[VlFWHKxbHnm[ZJifGmxbjDhd5NigQ>? MkDpNlQhcA>? NVnUOlFtSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkAzPCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVEvQDFizszN MVmyOVQ3QDB|OR?=
DU145 cells NVvo[mN6S3m2b4TvfIlkcXS7IHHzd4F6 NHPab4g1QCCq M2DFS2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZnwxIxiR1m1NF0yNjhzIN88US=> MUeyOFg{PTd6Nh?=
human SKBR3 cells NXXsSHFqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEKyXGI1QCCq MkXpS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2tDWjNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlc1KM7:TR?= NFnYeGkzOjh3MEKxOC=>

... Click to View More Cell Line Experimental Data

体内研究 ABT-751每天按100和75 mg/kg剂量单独作用于Calu-6移植瘤模型,具有显著抗癌活性,与Cisplatin联用时, ABT-751进一步延迟肿瘤生长,这种作用存在剂量依赖性。ABT-751单独作用于HT-29 结肠移植瘤模型,也具有显著抗癌活性,与5-FU联用时,也进一步延迟肿瘤生长,这种作用也存在剂量依赖性。[2] ABT-751 作用于患淋巴癌的犬,具有剂量限制性毒性,伴随着呕吐,腹泻,厌食,最大耐受剂量(MTD)为350 mg/m(2) PO q24h。而且, ABT-751按最大耐受剂量(MTD)350 mg/m(2) PO q24h 处理,平均AUC和Cmax分别为5.55 μg-hour/mL和0.9 μg/mL。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
- 合并
  • Cell lines: HOS, HTB-186 Daoy, TC-71, RD, SK-N-AS, SK-N-DZ, LD 和KCNR
  • Concentrations: 0 到100 μM
  • Incubation Time: 72 小时
  • Method: 培养在含FBS的1640 RPMI培养基上的细胞接种在96孔组织培养板上,设计为最适合铺满单层细胞生长(HOS, HTB-186 Daoy细胞每孔5,000个;TC-71, RD, SK-N-AS, SK-N-DZ, LD细胞每孔10,000个; KCNR细胞每孔30,000个), 且具有一个自动化的,多通道的移液管系统。 细胞在37oC/5% CO2下温育24小时,然后用1.25% DMSO/H2O(对照组), VCR (0.1–1000 nM), ABT-751 (0.1 nM–100 μM), 和Combretastatin (0.1–1000 nM) 处理72 小时。 细胞和三氯乙酸在4oC下混合,终浓度为10%, 冲洗, 在室温下烘干,用溶于1%乙酸的SRB染色,然后用Tris碱溶液染料。在540和 405 nm 双波长下,在Bio-Tek EL 340 UV 读数板上测定光密度。
    (Only for Reference)
动物实验:[2]
- 合并
  • Animal Models: 注射Calu-6 NSCLC, HT-29 结肠, 和 HCT-116细胞的无胸腺小鼠
  • Dosages: 75 或100 mg/kg/day
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 74 mg/mL (199.24 mM)
Ethanol 12 mg/mL (32.3 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% propylene glycol, 5% Tween 80, 65% D5W
15 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 371.41
化学式

C18H17N3O4S

CAS号 141430-65-1
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00436852 Completed Drug: ABT-751|Procedure: quality-of-life assessment Disseminated Neuroblastoma|Recurrent Neuroblastoma Children''s Oncology Group|National Cancer Institute (NCI) January 2007 Phase 2
NCT00735878 Terminated Drug: ABT-751 and Carboplatin Non Small Cell Lung Cancer|Lung Cancer Konstantin Dragnev|Abbott|Dartmouth-Hitchcock Medical Center September 2004 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂

Microtubule Associated Signaling Pathway Map

相关Microtubule Associated产品

Tags: 购买ABT-751 (E7010) | ABT-751 (E7010)供应商 | 采购ABT-751 (E7010) | ABT-751 (E7010)价格 | ABT-751 (E7010)生产 | 订购ABT-751 (E7010) | ABT-751 (E7010)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID